Top 5 Stunning Updates on Hims & Hers in 2025
Hims & Hers 2025 โ Top 5 Breaking Developments Investors Must Know

๐ข Hims & Hers Stock Tumbles After Novo Nordisk Exit
In one of the most unexpected announcements of 2025, pharmaceutical giant Novo Nordisk has ended its weight-loss drug partnership with Hims & Hers.
โThis could shift the strategic direction of โ noted a CNBC analyst.
๐ด What Happened?
Novo Nordisk discontinued the collaboration related to GLP-1 weight loss medications, which were believed to be a game-changer for HIMS in the telehealth market.
๐ป Stock Impact After the Announcement
The stock fell over 12% within 24 hours, as reported by Investing.com.
Investors were shocked by the move, leading to a sell-off of HIMS shares across trading platforms.

๐ผ๏ธ Image Prompt 2:
A close-up of the HIMS stock ticker on a trading app with red downward arrows.
๐ข 2. Strong Revenue Numbers Still Impress in Q2 2025
Despite the shock exit, Hims & Hers released strong Q2 financials. With revenue climbing by 18% YoY, the company is still financially robust.
According to Yahoo Finance, HIMS posted revenues of $278 million, surpassing analyst expectations.
๐ท Resilience Amid Setbacks
The brandโs loyal customer base and D2C (Direct-to-Consumer) strategy are credited for the continued growth.

Table of Contents
๐ข 3. Positive Customer Sentiment Keeps Momentum Alive
While Wall Street is reacting nervously, customers are standing by the brand.
๐ฉ What Users Say
Hims & Hers has over 90% satisfaction on trust platforms, thanks to:
- Discreet delivery
- Easy telehealth consultations
- Affordable pricing compared to traditional healthcare
This positive sentiment is helping the company keep up the momentum.
โEven without Novo Nordisk, theyโve built a strong brand image,โ says a Morningstar review.
๐ข 4. Analysts Remain Divided โ Buy or Sell?
๐ Mixed Analyst Opinions
According to NASDAQ, HIMS shares are rated Hold by most analysts, with a few marking it as a speculative Buy due to low current valuation.
๐ง Pros of Investing Now:
- Strong brand recall
- Growing consumer base
- Potential future partnerships
โ ๏ธ Cons of Investing Now:
- No longer backed by a pharma heavyweight
- Market volatility
- Uncertainty in long-term weight loss strategy
๐ข 5. What’s Next for Hims & Hers?
๐ฎ Hims & Hers Plans to Go Solo in Weight Loss Market
Though Novo Nordisk exited the scene, Hims & Hers has hinted at developing its own weight-loss offerings. This includes natural supplements, behavioral coaching, and new medical partnerships.
โWe are committed to helping millions of Americans lose weight in a healthy and accessible way,โ said a company spokesperson.
๐ต Final Thoughts: Should You Trust Hims & Hers in 2025?
Despite a recent setback, ITcontinues to show positive growth and adaptability. For long-term investors and loyal customers, the brand remains a strong player in the digital health space.
๐ข Power Takeaway:
- ๐ Short-Term Hit: Stock dropped due to Novo exit
- ๐ Long-Term Play: Brand is still thriving with user growth
- ๐ก Your Move: Monitor closely, but donโt count them out
๐ Quick Recap Table
Metric | Value/Info |
---|---|
Stock Drop | 12% (June 2025) |
Q2 Revenue | $278M (Up 18%) |
Customer Satisfaction | 90%+ |
Analyst Recommendation | Hold / Speculative Buy |
Weight Loss Strategy | Solo development & coaching model |
โ Pros
- Massive health market demand
- Personalized health products
- Affordable telehealth services
โ Cons
- Stock volatility
- Pharma reliance
- Rising competition in telemedici
๐ External Resources (For Further Reading):
- Investing.com โ HIMS Stock Falls After Novo Nordisk Exit
- Yahoo Finance โ HIMS Stock Data
- NASDAQ โ HIMS Market Activity
- https://mysportinfo.com/https-mysportinfo-comnyc-weather-today/
Leave a Reply